Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. furnished a report highlighting a new peer-reviewed publication on its lead drug candidate Piclidenoson in canine osteoarthritis. The article in Frontiers in Veterinary Science describes a study where oral Piclidenoson produced statistically significant improvements in mobility and pain in dogs, with a favorable safety profile.
Piclidenoson is being developed for veterinary use by Vetbiolix under a licensing agreement potentially valued at up to $325 million in upfront, milestone and royalty payments, and is currently in an advanced Phase 2 clinical study in dogs. Can-Fite also reiterates its broader clinical pipeline, including Piclidenoson in psoriasis Phase 3 trials and Namodenoson in multiple Phase II/III studies in liver and oncology indications, all supported by safety experience in over 1,600 patients.
Can-Fite BioPharma Ltd. reported encouraging Phase 2a results for Namodenoson in advanced pancreatic cancer and plans a Phase 2b study combining the drug with immunotherapy. The Phase 2a trial showed a favorable safety profile, treatment extending beyond 16 months in some patients, stable disease in over 30% of evaluable patients, and 35% of patients remaining on therapy and follow up. The company intends to discuss the Phase 2b study design and potential partnerships with leading oncology companies at the BIO International Convention. Namodenoson has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also in trials for liver cancer and MASH.
Can-Fite BioPharma Ltd. reported positive Phase 2a data for its drug namodenoson in advanced pancreatic cancer. In this fully enrolled, 20-patient open-label study, namodenoson showed a favorable safety profile and preliminary signs of durable disease stabilization in heavily pretreated patients.
About 35% of patients remain on therapy, including one treated for more than 16 months, suggesting potential for longer-term benefit in this difficult-to-treat setting. The trial met its primary safety endpoint, with no new safety signals and consistency with prior namodenoson experience. Full efficacy analyses, including progression-free and overall survival, are planned, with top-line results expected to be presented at an upcoming clinical conference.
Can-Fite BioPharma Ltd. will hold its 2026 Annual General Meeting of Shareholders on May 28, 2026 at its offices in Ramat Gan, Israel. Shareholders of record as of May 4, 2026 may vote.
Items include re-electing director Abraham Sartani, increasing authorized share capital from 14,000,000 to 30,000,000 ordinary shares, and granting 24,000 stock options each to Chairman Dr. Pnina Fishman and CEO/CFO Motti Farbstein. Investors will also vote on re-appointing Kost Forer Gabbay & Kasierer (Ernst & Young Global member) as independent auditors for 2026 and authorizing the audit committee to set their compensation, and will review the auditor’s report and consolidated financial statements for the year ended December 31, 2025.
Can-Fite BioPharma Ltd. director Tamir Ilan reported his initial beneficial ownership, consisting of options to purchase 16,000 Ordinary Shares. These options have an exercise price of $2.25 per share and expire on April 25, 2036.
None of the options are currently vested. All 16,000 options vest in sixteen equal quarterly installments from April 25, 2026 through January 25, 2030, subject to his continued service with the company. The options were granted under Can-Fite’s share option plans and are held through a trustee to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance. The exercise price was originally set at NIS 6.767 and is presented in U.S. dollars using a Bank of Israel exchange rate of NIS 3.003 = USD 1.00 as of April 20, 2026.
Can-Fite BioPharma Ltd. director Regev Guy filed an initial ownership statement showing direct holdings of options to purchase Ordinary Shares and a small number of shares. He reports options over 16,000 shares at an exercise price of $2.18 per share plus several smaller, higher-priced option grants and 8 Ordinary Shares. The options were granted under the company’s share option plans, with some fully vested and others vesting in scheduled quarterly installments through 2030.
Can-Fite BioPharma Ltd. filed a prospectus registering for resale up to 3,294,898 ordinary shares represented by 1,647,449 ADSs, consisting primarily of shares issuable upon exercise of repriced warrants. The offering is by selling shareholders; the company will receive proceeds only if warrants are exercised for cash. The ADS ratio is 2 ordinary shares per ADS and there are 4,285,093 ordinary shares outstanding as of March 30, 2026.
Can-Fite BioPharma Ltd. files a Form F-3 resale registration to permit selling shareholders to resell up to 3,294,898 ordinary shares represented by 1,647,449 ADSs, consisting primarily of shares issuable upon exercise of repriced warrants.
The registration covers New Warrants and Placement Agent Warrants with an exercise price of $5.00 per ADS, exercisable for two years from the registration effective date; holders may exercise on a cashless basis under specified conditions. The company will not receive proceeds from resale transactions but may receive proceeds if warrants are exercised for cash (full cash exercise would yield approximately $8.01M). Shares outstanding were 4,285,093 ordinary shares as of March 30, 2026; pro forma outstanding assuming full warrant exercise is 7,579,991 ordinary shares.